Your new experience awaits. Try the new design now and help us make it even better

MINI REVIEW article

Front. Pharmacol.

Sec. Cardiovascular and Smooth Muscle Pharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1688338

This article is part of the Research TopicCracking the Code of Smooth Muscle Dysfunction: From Molecular Mechanisms to Therapeutic InnovationsView all articles

Tanshinone I, Tanshinone IIA, and Cryptotanshinone: Key Bioactive Components Modulating Vascular Smooth Muscle Cell Function

Provisionally accepted
Jixin  LiJixin LiWenru  WangWenru WangHongbo  HuangHongbo HuangRuiling  ZhouRuiling ZhouZhenyu  YangZhenyu YangZhijie  CuiZhijie CuiZelong  NiuZelong NiuShengnan  ShiShengnan ShiPeili  WangPeili Wang*
  • China Academy of Chinese Medical Sciences, Beijing, China

The final, formatted version of the article will be published soon.

Cardiovascular diseases (CVDs) remain the leading cause of mortality among non-communicable diseases worldwide. Vascular smooth muscle cells (VSMCs), as the predominant cellular component of the tunica media, are essential for maintaining vascular homeostasis through phenotype-dependent regulation of vascular tone, blood pressure, and hemodynamics. Under pathological conditions such as hypoxia or inflammation, VSMCs undergo phenotypic switching from a contractile to a synthetic state. This transition is characterized by excessive proliferation, migration, and pro-inflammatory secretion, all of which contribute to the progression of atherosclerosis and restenosis. Tanshinones, bioactive diterpenoid compounds isolated from Salvia miltiorrhiza, exert cardioprotective effects through their anti-inflammatory, antioxidant, and VSMC-modulating activities. Increasing evidence suggests that tanshinones attenuate maladaptive VSMC behaviors by regulating calcium signaling, modulating programmed cell death pathways, and suppressing pro-inflammatory signaling cascades. These actions collectively inhibit phenotypic switching and mitigate vascular remodeling and plaque formation. Despite these advances, a comprehensive understanding of the precise molecular targets and signaling networks of tanshinones in VSMCs is still lacking. This review aims to integrate current evidence to delineate tanshinone-mediated VSMC regulatory mechanisms, provide mechanistic insights, and identify potential therapeutic targets for phenotype-directed interventions in CVDs.

Keywords: Cardiovascular diseases1, Vascular smooth muscle cells2, Tanshinone I3, TanshinoneIIA4, Cryptotanshinone5, Sodium tanshinone IIA sulfonate6

Received: 19 Aug 2025; Accepted: 29 Sep 2025.

Copyright: © 2025 Li, Wang, Huang, Zhou, Yang, Cui, Niu, Shi and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Peili Wang, wplggyx777@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.